The Gemma termination removes near-term pipeline catalysts for a micro-cap biotech with no approved products. Monitor for any restructuring or cash runway update in the next 10-Q. The lease exit saves future rent but the $2.3M fee is material relative to a $19M market cap.
Price Chart
Executive Summary
Passage Bio terminated its research collaboration with Gemma Biotherapeutics for Huntington's disease and epilepsy programs, losing options for four new CNS indications. Separately, the company paid $2.3 million to exit its 37,000 sq ft Philadelphia office lease, consistent with its remote-only model. The Gemma termination removes a key pipeline catalyst for a $19M market cap biotech with no approved products.
Key Facts
- Terminated Gemma Biotherapeutics collaboration covering Huntington's disease and Temporal Lobe Epilepsy programs, plus options for four new CNS indications.
- Paid $2.3 million termination fee to exit 37,000 sq ft office lease at 2005 Market Street, Philadelphia.
- Company operates as remote-only with no headquarters; lease was set to expire December 2031.
- Market cap is approximately $19 million with no disclosed revenue from product sales.
Financial Impact
$2.3 million cash lease termination fee; loss of R&D collaboration value undisclosed
Risk Factors
- Loss of partnered R&D for Huntington's and epilepsy programs may delay or end those programs.
- Cash burn rate unknown; $2.3M lease termination reduces cash reserves.
- No disclosed revenue or near-term catalysts remain visible.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-066956 |
| Document: 0001104659-26-066956-index-headers.html | 0001104659-26-066956 |
| Document: 0001104659-26-066956-index.html | 0001104659-26-066956 |
| Document: 0001104659-26-066956.txt | 0001104659-26-066956 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 3, 2026 29d ago | S-4/A / 425 | $4.75 $5.00 | ▼ −5.26% | ▼ −6.41% | $4.33 (+8.84%) |
Sep 3, 2026 29d ago | 8-K | $4.75 $5.00 | ▲ +5.26% | ▲ +6.41% | $4.33 (−8.84%) |
Jun 24, 2026 14w ago | 425 | $4.33 $4.58 | ▼ −5.77% | ▼ −4.21% | $4.33 (+0.00%) |
Jun 24, 2026 14w ago | 425 | $4.33 $4.58 | ▼ −5.77% | ▼ −4.21% | $4.33 (+0.00%) |
Jun 24, 2026 14w ago | 8-K | $4.33 $4.58 | ▼ −5.77% | ▼ −4.21% | $4.33 (+0.00%) |
May 27, 2026 18w ago | 8-K | $5.71 $6.00 | ▼ −5.08% | ▼ −4.76% | $4.33 (+24.17%) |
Apr 20, 2026 23w ago | 8-K | $6.25 $5.71 | ▼ −8.64% | ▼ −9.55% | $4.33 (−30.72%) |
Apr 20, 2026 23w ago | Press Release | $6.25 $5.71 | ▼ −8.64% | ▼ −9.55% | $4.33 (−30.72%) |
Apr 7, 2026 25w ago | DEFA14A | $8.22 $10.86 | ▲ +32.20% | ▲ +26.87% | $4.33 (−47.29%) |
Mar 3, 2026 30w ago | Press Release | $8.00 $8.51 | ▲ +6.38% | ▲ +6.85% | $4.33 (−45.88%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access